Drug intelligence / Profile preview

IL2103

Development stage: Preclinical
Lead developer: iLeadBMS
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Parenteral

Overview

IL2103 is a preclinical-stage small molecule proteolysis-targeting chimera (PROTAC) designed to degrade poly (ADP-ribose) polymerase (PARP). Developed by iLeadBMS, a spin-off biotechnology company of Ildong Pharmaceutical Group, IL2103 is being investigated for the treatment of solid tumors. By utilizing a targeted protein degradation (TPD) mechanism, IL2103 aims to selectively eliminate PARP proteins, potentially offering a more durable and effective therapeutic option compared to traditional PARP inhibitors.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)

Beyond the preview

Go deeper on IL2103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL2103.

Explore the full profile